These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 36553327)

  • 1. How Compounding Pharmacies Fill Critical Gaps in Pediatric Drug Development Processes: Suggested Regulatory Changes to Meet Future Challenges.
    MacArthur RB; Ashworth LD; Zhan K; Parrish RH
    Children (Basel); 2022 Dec; 9(12):. PubMed ID: 36553327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential risks of pharmacy compounding.
    Gudeman J; Jozwiakowski M; Chollet J; Randell M
    Drugs R D; 2013 Mar; 13(1):1-8. PubMed ID: 23526368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of outsourcing facilities in overcoming drug shortages.
    Mattingly AN
    J Am Pharm Assoc (2003); 2021; 61(1):e110-e114. PubMed ID: 32943335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Compounded Nonsterile Preparations and FDA-Approved Commercially Available Liquid Products for Children: A North American Update.
    Parrish RH; Ashworth LD; Löbenberg R; Benavides S; Cies JJ; MacArthur RB
    Pharmaceutics; 2022 May; 14(5):. PubMed ID: 35631618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the Amount of Compounded Chemotherapy Drugs: A Comparison Between Nine Compounding Pharmacies.
    Bajorek SR; Hazzah TN; Chretin JD; Mills TN; McKee TS; Frank JR; Benvin-Guzzo JL; Clifton KA; Bergman PJ
    Vet Comp Oncol; 2024 Aug; ():. PubMed ID: 39164199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinguishing between compounding facilities and the development of the 503B bulk drug substance list.
    Gianturco SL; Mattingly AN
    J Am Pharm Assoc (2003); 2021; 61(1):e8-e11. PubMed ID: 32713748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current Trends and Emerging Priorities in Compounded Preparations for Children.
    Parrish RH
    Int J Pharm Compd; 2018; 22(5):358-366. PubMed ID: 30384335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update on medical and regulatory issues pertaining to compounded and FDA-approved drugs, including hormone therapy.
    Pinkerton JV; Pickar JH
    Menopause; 2016 Feb; 23(2):215-23. PubMed ID: 26418479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retrospective survey of compounded medications for children in Japan.
    Saito J; Akabane M; Ishikawa Y; Iwahashi K; Nakamura H; Yamatani A
    Eur J Pharm Biopharm; 2020 Oct; 155():122-127. PubMed ID: 32853693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Compounding pharmacy conundrum: "we cannot live without them but we cannot live with them" according to the present paradigm.
    Guharoy R; Noviasky J; Haydar Z; Fakih MG; Hartman C
    Chest; 2013 Apr; 143(4):896-900. PubMed ID: 23412546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Crushability Analysis of Immediate-Release Oral Tablets and Capsules from the 2020-22 FDA Novel Drug Approvals.
    Saei K; Schweighardt A; Zhao F
    Int J Pharm Compd; 2024; 28(5):364-372. PubMed ID: 39405567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Packaging and labeling of pharmaceutical products obtained from the internet.
    Veronin M
    J Med Internet Res; 2011 Feb; 13(1):e22. PubMed ID: 21324833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pharmacist-driven Food and Drug Administration incident surveillance and response program for compounded drugs.
    Janusziewicz AN; Glueck SN; Park SY; Nguyen DN; Rimmel SC; Cascio LA; Doh GY; Martin-Yeboah GF
    Am J Health Syst Pharm; 2021 Jul; 78(15):1438-1443. PubMed ID: 33889929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Considerations in Qualifying Critical Suppliers.
    Summers A
    Int J Pharm Compd; 2023; 27(6):461-466. PubMed ID: 38100663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the Most Frequently Prescribed Extemporaneously Compounded Veterinary Medications at a Large Independent Community Pharmacy.
    Karara AH; Hines R; Demir Z; Nnorom B; Horsey R; Twigg G
    Int J Pharm Compd; 2016; 20(6):461-467. PubMed ID: 28339384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmaceutical compounding or pharmaceutical manufacturing? A regulatory perspective.
    Timko RJ; Crooker PE
    Int J Pharm Compd; 2014; 18(2):101-11. PubMed ID: 24881112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Compounding warning letters to 503A facilities between 2017 and 2021.
    Zhang Q; Liu X; Qian Y; Liu D; Cao L; Li H; Xiao H; Liu W
    J Am Pharm Assoc (2003); 2023; 63(5):1583-1591. PubMed ID: 37414280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of Extemporaneous Prescriptions Prescribed by Dermatovenerologists in Latvia and Comparison with Standardized Compounded Preparation Monographs of Germany and USA.
    Kiseļova O; Mauriņa B; Šidlovska V
    Medicina (Kaunas); 2020 Jan; 56(1):. PubMed ID: 31936697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EVALUATION OF CASES WITH THE USAGE OF COMMERCIALLY AVAILABLE TABLETS IN THE PEDIATRIC FORMULA.
    Kuriata E; Sawicki W
    Acta Pol Pharm; 2015; 72(3):551-8. PubMed ID: 26642663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence, determinants, and characteristics of extemporaneous compounding in Jordanian pharmacies.
    AlKhatib HS; Jalouqa S; Maraqa N; Ratka A; Elayeh E; Al Muhaissen S
    BMC Health Serv Res; 2019 Nov; 19(1):816. PubMed ID: 31703672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.